Metastatic hormone-sensitive prostate cancer (mHSPC)

Bayer Identifier:
22911
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available

Trial purpose

Key Participants Requirements

Sex

N/A

Age

N/A

Trial summary

Enrollment Goal
N/A
Trial Dates
null - Today
Phase
N/A (Not Applicable)
Could I Receive a placebo
N/A
Products
Darolutamide, BAY 1841788
Accepts Healthy Volunteer
N/A

Trial design

Clinical use of Androgen-Receptor PAthwAy inhibitors as Triplet therapy for metastatic hormone sensitive prostate cancer (ARAAT)
Trial Type
Observational
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
Open Label
Assignment
N/A
Trial Arms
N/A